Home About us Contact
|
Home About us Contact | ||
|
|
||
Factor V Inhibitor (factor + v_inhibitor)
Selected AbstractsSpontaneous resolution of acquired factor V inhibitor associated with ovarian carcinomaINTERNATIONAL JOURNAL OF LABORATORY HEMATOLOGY, Issue 4 2007E. O. MAUGHAN Summary A 74-year-old lady who presented initially with loin pain and haematuria, then melaena was found to have a prothrombin time ratio (PTR) > 10 and activated partial thromboplastin time ratio (APTTR) > 7. A factor V inhibitor was diagnosed. She was managed with supportive care and the FV inhibitor resolved. A few weeks later she developed abdominal swelling and ascites and was found to have an ovarian tumour. This is the first case, as far as we are aware, of a malignancy-associated FV antibody that has spontaneously remitted before overt presentation of the tumour and illustrates the value of adopting an expectant approach to the management of acquired FV inhibitors. [source] Severe Hemorrhagic Complication Due to Acquired Factor V Inhibitor After Single Exposure to Bovine Thrombin ProductJOURNAL OF CARDIAC SURGERY, Issue 6 2000Michio Kajitani M.D., Ph.D. Our patient underwent emergency repair of acute aortic dissection and coronary artery bypass grafting. The patient developed leg wound infection at the saphenous vein harvest site, which was debrided and left open. Attempt to reclose the leg wound 1 month later was complicated by a life-threatening hemorrhage with markedly elevated activated partial thromboplatin time. There was no evidence of infection or disseminated intravascular coagulation, and further study identified low factor V level with positive factor V inhibitor. Treatment with plasmapheresis and steroid successfully reversed the coagulopathy. Detailed case review failed to reveal exposure to any thrombin products other than the one used for the aortic dissection repair. This case was unusual because only a single exposure to this product resulted in severe hemorrhagic complication 1 month after surgery. [source] An acquired factor V inhibitor associated with defective factor V function, storage and binding to multimerin 1JOURNAL OF THROMBOSIS AND HAEMOSTASIS, Issue 2 2008S. B. JEIMY [source] Acquired factor V inhibitor in a context of sepsis and disseminated intravascular coagulation,AMERICAN JOURNAL OF HEMATOLOGY, Issue 2 2010Anne Tessier-Marteau No abstract is available for this article. [source] Response of factor V inhibitor to rituximab in a patient who received liver transplantation for primary biliary cirrhosisAMERICAN JOURNAL OF HEMATOLOGY, Issue 4 2004Eric Chun-Yet Lian Abstract A 43-year-old patient developed factor V inhibitor 6 months after liver transplantation for primary biliary cirrhosis in association with Sjögren's syndrome/systemic lupus erythematosus. She suffered from ecchymoses in the lower extremities. The factor V inhibitor was eradicated after 10 weekly doses of 375,500 mg/m2 rituximab. Am. J. Hematol. 77:363,365, 2004. © 2004 Wiley-Liss, Inc. [source] Acquired factor V inhibitor in a critically ill patientANAESTHESIA, Issue 9 2009C. J. Morris Summary Acquired inhibitor of factor V is a rare condition with a variety of clinical manifestations, from extremely mild to life threatening haemorrhage. We present a case from our intensive care unit as a reminder of the less common causes of elevated prothombin and activated partial thromboplastin times, and how knowledge of the variable presentation may aid management. [source] | ||||||||||